TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis
Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple ...
Feb 21, 2017
0
2